Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates

Journal of Nuclear Medicine

Volumn 45, Issue 1, 2004, Pages 30-39

  Griffiths, Gary L ^a,b   Chang, Chien Hsing ^a,b   McBride, William J ^a,b   Rossi, Edmund A ^a,b   Sheerin, Agatha ^a,b   Tejada, German R ^a,b   Karacay, Habibe ^c   Sharkey, Robert M ^c   Horak, Ivan D ^a,b   Hansen, Hans J ^a,b   Goldenberg, David M ^c  

^a IMMUNOMEDICS INC   (United States)

^b IBC Pharmaceuticals Inc   (United States)

^c GARDEN STATE CANCER CENTER   (United States)

Author keywords

2 step pretargeting; 67Ga; 68Ga; Bispecific antibodies; PET

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CHELATE; DNA; GALLIUM 68; GLYCINE; HAPTEN; HISTAMINYLSUCCINYLGLYCINE; IMMUNOGLOBULIN F(AB) FRAGMENT; INOSINE PHOSPHATE; PEPTIDE; UNCLASSIFIED DRUG; CHELATING AGENT; DIAGNOSTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; GADOLINIUM IMP241; OLIGOPEPTIDE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ARTICLE; COLON CANCER; CONTROLLED STUDY; IN VIVO STUDY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; COLON TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EVALUATION; HUMAN; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MOUSE; NUDE MOUSE; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; CELL LINE, TUMOR; CHELATING AGENTS; COLONIC NEOPLASMS; HAPTENS; HUMANS; INDICATORS AND REAGENTS; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; OLIGOPEPTIDES; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1842503937     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. 68Ga generator with alpha-ferric oxide support. Int J Appl Radiat Isot. 1988;39:49-51.
2. Loc'h CH, Maziere B, Comar D. A new generator for ionic gallium-68. J Nucl Med. 1980;21:171-174.
3. Neirinckx RD, Davis MA. Potential column chromatography for ionic Ga-68. II. Organic ion exchangers as chromatographic supports. J Nucl Med. 1980;21:81-83.
4. 68Ga generator systems for radiopharmaceutical production. Int J Appl Radiat Isot. 1984;35:521-524.
5. Kulprathipanja S, Hnatowich DJ. A method for determining the pH stability range of gallium radiopharmaceuticals. Int J Appl Radiat Isot. 1977;28:229-233.
6. Schuhmacher J, Klivényi G, Matys R, et al. Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate suitable for immunoscintigraphy with positron emission tomography. Cancer Res. 1995;55:115-123.
7. V6/anti-gallium chelate antibodies. J Nucl Med. 1998;39:1769-1776.
8. Wu C, Jagoda E, Brechbiel M, et al. Biodistribution and catabolism of Ga-67-labeled anti-Tac dsFv fragment. Bioconjug Chem. 1997;8:365-369.
9. Sun Y, Anderson CJ, Pajeau T, et al. Indium(III) and gallium(III) complexes of bis(aminoethanethiol) ligands with different denticities: stabilities, molecular modeling and in vivo behavior. J Med Chem. 1996;39:458-470.
10. Green MA, Mathias CJ, Neumann WL, Fanwick PE, Janik M, Deutsch EA. Potential gallium-68 tracers for imaging the heart with PET: evaluation of four gallium complexes with functionalized tripodal tris(salicylaldimine) ligands. J Nucl Med. 1993;34:228-233.
11. Kung HF, Liu BL, Mankoff D, et al. A new myocardial imaging agent: synthesis, characterization, and biodistribution of Ga-68-BAT-TECH. J Nucl Med. 1990;31:1635-1645.
12. 68Ga-labeled chelates for clinical use. Nucl Med Biol. 1994;21:897-899.
13. 68Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;12:1751-1757.
14. Schuhmacher J, Kaul S, Klivenyi G, et al. Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res. 2001;61:3712-3717.
15. Luyt LG, Katzenellenbogen JA. A trithiolate tripodal bifunctional ligand for the radiolabeling of peptides with gallium(III). Bioconjug Chem. 2002;13:1140-1145.
16. +) complexes with cis,cis-1,3,5-triamino-cyclohexane-N,N′,N″-triacetic acid derivatives. Nucl Med Biol. 2001;28:695-701.
17. Smith-Jones PM, Stolz B, Bruns C, et al. Gallium-67/gallium-68-[DFO]- octreotide: a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors - synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med. 1994;35:317-325.
18. 111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem. 2002;13:530-541.
19. 67Ga-labeled antibody via 1B4M or C-NOTA chelates. Nucl Med Biol. 1997;24:225-230.
20. Ugur O, Kothari PJ, Finn RD, et al. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol. 2002;29:147-157.
21. 225Ac radioimmunopharmaceuticals. Appl Radiat Isot. 2002;57:841-847.
22. 111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;28:1319-1325.
23. 177Lu chelation properties of selected macrocyclic and acyclic ligands. Nucl Med Biol. 1998;25:117-125.
24. Boerman OC, Kranenborg MHGC, Oosterwijk E, et al. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res. 1999;59:4400-4405.
25. 188Re-labeled peptide. Bioconjug Chem. 2000;41:842-487.
26. Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther. 2002;1:553-563.
27. Reardan DT, Meares CF, Goodwin DA, et al. Antibodies against metal chelates. Nature. 1985;316:265-268.
28. Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W. Pre-targeted immunoscintigraphy of murine tumors with In-111-labeled bifunctional haptens. J Nucl Med. 1988;29:226-234.
29. LeDoussal J-M, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989;30:1358-1366.
30. Stickney DR, Anderson LD, Slater JB, et al. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res. 1991;51:6650-6655.
31. Goodwin DA, Meares CF, McTigue M, et al. Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake. J Nucl Med. 1992;33:2006-2013.
32. Barbet J, Kraeber-Bodere F, Vuillez JP, Gautherot E, Rouvier E, Chatal JF. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm. 1999;14:153-166.
33. Janevik-Ivanovska E, Gautherot E, Hillairet de Boisferon M, et al. Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconjug Chem. 1997;8:526-533.
34. Morel A, Darmon M, Delaage M. Recognition of imidazole and histamine derivatives by monoclonal antibodies. Mol Immunol. 1990;27:995-1000.
35. Sharkey RM, McBride WJ, Karacay H, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res. 2003;63:354-363.
36. Dangles O, Guibe F, Balavoine G, Lavielle S, Marquet A. Selective cleavage of the allyl and allyloxycarbonyl groups through palladium-catalyzed hydrostannolysis with tributyltin hydride: application to the selective protection-deprotection of amino acid derivatives and in peptide synthesis. J Org Chem. 1987;52:4984-4993.
37. Holliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA. 1993;90:6444-6448.
38. 32P labeling of a humanized anti-carcinoembryonic antigen (hMN-14) antibody fragment. Cancer Res. 1995;55(suppl):5968-5972.
39. Pei XY, Holliger P, Murzin AG, Williams RL. The 2.0-Å resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3. Proc Natl Acad Sci USA. 1997;94:9637-9642.
40. Schuhmacher J, Klivényi G, Kaul S, et al. Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET. Nucl Med Biol. 2001;28:821-828.